MVC-COV1901
Sponsors
Medigen Vaccine Biologics Corp., Chang Gung Memorial Hospital
Conditions
Breakthrough InfectionCOVID-19COVID-19 VaccineCovid19 Vaccine
Phase 1
A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19
CompletedNCT04487210
Start: 2020-10-07End: 2021-12-06Updated: 2022-01-31
The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine
NCT05132855
Start: 2021-11-30End: 2023-04-30Updated: 2022-07-25
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19
CompletedNCT05216601
Start: 2022-05-06End: 2022-11-30Updated: 2023-03-15
Phase 3
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults
CompletedNCT05011526
Start: 2021-10-08End: 2022-05-21Updated: 2022-09-30
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above
CompletedNCT05198596
Start: 2022-07-30End: 2023-03-30Updated: 2023-10-23
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222
CompletedNCT05426343
Start: 2022-07-09End: 2023-01-07Updated: 2023-10-23